Core Strategy - The company is transitioning from Jakafi to a hematology/oncology and immunology (hem/onc I&I) company, aiming for a steeper growth curve post-2029 with sustainable revenue, earnings, and cash flow [2] Business Potential - The core business, excluding Jakafi, has the potential to match Jakafi's size by 2029, indicating significant growth opportunities [2] Pipeline Projects - The company has seven late-stage pipeline projects that will enhance the core business, particularly in hematology, which is a central focus of the company [3]